Penumbra EBIT per Share
The EBIT per Share of Penumbra (PEN) as of Aug 12, 2026 is 4.80 USD. In the previous year, EBIT per Share was 0.24 USD — a change of 1,933.09% (higher).
Get this data via API
Financial Data API
EBIT per Share
4.80USD
YoY
1,933.09%
Last updated:
EBIT per Share of Penumbra is 2026 4.80 USD. EBIT per Share of Penumbra was 2025 0.24 USD. It decreases by 1,933.09% higher compared to the previous year.
Access this data via the Eulerpool API
Penumbra Stock analysis
What does Penumbra do? Penumbra Inc is an American company specializing in medical technology. It was founded in 2004 and is headquartered in Alameda, California. The company has branches and subsidiaries worldwide. It offers various products for the treatment of strokes, aneurysms, vascular injuries, and other medical conditions.
The history of Penumbra Inc began with the founder and CEO Adam Elsesser's vision to develop innovative technologies to help patients with challenging medical conditions. The company started with just one product, the Penumbra 3D Coiling Technology, which is used for the treatment of brain aneurysms.
Penumbra Inc's business model is based on the development and marketing of innovative medical devices and technologies to assist surgeons and specialists in treating their patients better. The company conducts intensive research and development to create new products that meet market demand.
Penumbra Inc is divided into different divisions to offer a comprehensive range of medical tools and devices to its customers. The main divisions of the company are Neuro, Vascular, and Oncology.
Under the Neuro division, Penumbra Inc offers a wide range of devices and technologies for the treatment of strokes and trauma. This includes the Penumbra Coil 400, used for treating intracranial aneurysms, and the Penumbra Jet 7 Reperfusion Catheter, an innovative technology for restoring blood flow in stroke patients' brains.
The Vascular division of Penumbra Inc provides devices for the treatment of vascular diseases, such as endovascular repairs of aortic aneurysms. This division utilizes the innovative Penumbra SMART Coil technology, which provides improved handling and safety.
The Oncology division of Penumbra Inc focuses on developing technologies to enhance healthcare for cancer patients. This includes innovative drug delivery devices, such as the Penumbra System used in brachytherapy.
Penumbra Inc is a leading provider of medical devices and technologies used in the treatment of complex medical conditions. Over the past decade, the company has established its reputation in the industry. Continuous investment in research and development and a focus on patient and medical professionals' needs have solidified Penumbra Inc's success in the international market. Penumbra is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Penumbra stock
EBIT per Share of Penumbra is 4.80 USD in 2026.
EBIT per Share of Penumbra changed from 0.24 USD to 4.80 USD, representing a 1,933.09% change. The value is higher than the previous year.
On Eulerpool you can find the complete historical development of EBIT per Share Penumbra since 2006 – with annual values, charts, and detailed analysis.
EBIT per Share measures operating profit allocated to each outstanding share.
Access this data via the Eulerpool API
Income Statement — Penumbra
All Key Metrics — Penumbra
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth